[1] Russo AF. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. Annual Review of Pharmacology and Toxicology 2015, 55: 533-552.
[2] Russo A, Coppola G, Pierelli F, Parisi V, Silvestro M, Tessitore A, et al. Pain Perception and Migraine. Frontiers in Neurology 2018, 9.
[3] Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386: 2287-2323.
[4] Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain 2015, 16: 58.
[5] Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia 2013, 33: 289-290.
[6] Tinsley A, Rothrock JF. What Are We Missing in the Diagnostic Criteria for Migraine? Current Pain and Headache Reports 2018, 22: 1-5.
[7] Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008, 71: 848-855.
[8] Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson M. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). The Journal of Headache and Pain 2019, 20.
[9] Charles A. Migraine. N Engl J Med 2017, 377: 553-561.
[10] Huang T, Lai T, Taiwan Headache Society TGSO. Medical Treatment Guidelines for Preventive Treatment of Migraine. Acta neurologica Taiwanica 2017, 26: 33.
[11] Hsu YC, Lin KC, Taiwan HST. Medical Treatment Guidelines for Acute Migraine Attacks. Acta Neurol Taiwan 2017, 26: 78-96.
[12] Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache 2017, 57 Suppl 2: 47-55.
[13] Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci 2018, 39: 2097-2106.
[14] Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018, 392: 2280-2287.
[15] Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2017, 38: 1026-1037.
[16] Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 2018, 319: 1999-2008.
[17] Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018, 75: 1080-1088.
[18] Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2017, 38: 1442-1454.
[19] The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013, 33: 629-808.
[20] Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, 14: 1091-1100.
[21] de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. Clin Pharmacol Ther 2018, 103: 815-825.
[22] Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 2018, 38: 1960-1971.
[23] Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 2018, 18: 188.
[24] Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017, 377: 2123-2132.
[25] Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016, 15: 382-390.
[26] Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, 13: 1100-1107.
[27] Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015, 14: 1081-1090.
[28] Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol 2018, 75: 187-193.
[29] Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13: 885-892.
[30] Silberstein SD, Kudrow D, Saper J, Janelidze M, Smith T, Dodick DW, et al. Eptinezumab Results for the Prevention of Episodic Migraine over One Year in the PROMISE-1 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-1) Trial. HEADACHE 2018, 58: 1298.
[31] Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis. Clin Neurol Neurosurg 2017, 154: 74-78.
[32] Xu D, Chen D, Zhu L, Tan G, Wang H, Zhang Y, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials. Cephalalgia 2019: 1524364876.
[33] Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs 2019.
[34] Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018, 14: 338-350.
[35] Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. The Journal of Headache and Pain 2018, 19.
[36] Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? The Journal of Headache and Pain 2019, 20.
[37] Manoukian R, Sun H, Miller S, Shi D, Chan B, Xu C. Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking. The Journal of Headache and Pain 2019, 20.
[38] Gonzalez-Hernandez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalon CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 2018, 14: 25-41.
[39] Bell IM. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J Med Chem 2014, 57: 7838-7858.
[40] Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. The Journal of Headache and Pain 2019, 20.